Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William P Peters

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Archives of Internal Medicine|October 29, 2008
Cooperative groups are notWilliam P Peters
Cancer|September 26, 2003
Cost-effectiveness and lung cancer clinical trialsWei Du, Jaxk H Reeves, Shirish Gadgeel, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2011
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinomaGilberto de Lima Lopes, Jennifer S Dicksey, William P Peters, et al.
Cancer|January 8, 2005
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinomaEmilio Bria, Diana Giannarelli, Alessandra Felici, et al.
Cancer Research|May 17, 2008
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatmentChristina K Augustine, Yasunori Yoshimoto, Mukur Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancerWilliam P Petros, Gloria Broadwater, Donald Berry, et al.
Cancer|July 29, 2009
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanomaGeorgia M Beasley, Nicole McMahon, Gretchen Sanders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerWilliam P Petros, Penelope J Hopkins, Susan Spruill, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodesMonic J Stuart, William P Peters, Gloria Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Archives of Internal Medicine|October 29, 2008
Cooperative groups are notWilliam P Peters
Cancer|September 26, 2003
Cost-effectiveness and lung cancer clinical trialsWei Du, Jaxk H Reeves, Shirish Gadgeel, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2011
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinomaGilberto de Lima Lopes, Jennifer S Dicksey, William P Peters, et al.
Cancer|January 8, 2005
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinomaEmilio Bria, Diana Giannarelli, Alessandra Felici, et al.
Cancer Research|May 17, 2008
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatmentChristina K Augustine, Yasunori Yoshimoto, Mukur Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancerWilliam P Petros, Gloria Broadwater, Donald Berry, et al.
Cancer|July 29, 2009
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanomaGeorgia M Beasley, Nicole McMahon, Gretchen Sanders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerWilliam P Petros, Penelope J Hopkins, Susan Spruill, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodesMonic J Stuart, William P Peters, Gloria Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Pageof 2